New hope for lung cancer: experimental drug HC010 enters phase 2 trial
NCT ID NCT07169552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HC010 in people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal is to see if the drug can shrink tumors and control the disease. About 50 participants will receive the treatment, and researchers will monitor side effects and how long the benefits last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- New drug combo aims to shrink tough lung tumors
- New drug combo aims to outsmart lung cancer that resists immunotherapy
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation
- Lung cancer drug interaction study aims to uncover safe dosing